3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
CNS
1
Breast
1
Conditions
Ovarian Neoplasms
171
Fallopian Tube Neoplasms
85
Uterine Cervical Neoplasms
40
Carcinoma, Ovarian Epithelial
28
Endometrial Neoplasms
27
Neoplasms
14
Peritoneal Neoplasms
10
Colorectal Neoplasms
9
Brenner Tumor
9
Breast Neoplasms
9
Stomach Neoplasms
8
Recurrence
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Lung Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Carcinoma
5
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
4
Carcinoma, Hepatocellular
4
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Ovarian Diseases
3
Melanoma
3
Glioblastoma
3
Carcinoma, Renal Cell
3
Vulvar Neoplasms
2
Vaginal Neoplasms
2
Vaccinia
2
Uterine Neoplasms
2
Urinary Bladder Neoplasms
2
Interventions
niraparib
2
Trabectedin
1
Therapeutic Irrigation
1
Ocoxin
1
Diffusion
1
Dexamethasone
1
Blood Specimen Collection
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endocrine Gland Neoplasms
×
Bevacizumab
×
Gynecologic
×
Clear all
NCT04556071
2020-11-10
AVANIRA3
Jiangsu Cancer Institute & Hospital
Phase 2
Unknown
32 enrolled